Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.06 · Revenue $77.98M · 3 analysts
Est. EPS $0.57 · Revenue $112.37M · 3 analysts
Est. EPS $0.53 · Revenue $336.25M · 5 analysts
Est. EPS $-0.05 · Revenue $79.08M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $276.3M | +16.5% | +13.2% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $16.5M | +59.4% | +135.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +74.4% | +2.6% | +1.1% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +4.0% | +109.9% | +104.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +6.0% | +36.9% | +130.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $24.7M | +525.9% | -5.7% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +9.0% | +465.7% | -16.7% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 27.7% | -18.2% | -5.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 5.03x | +19.0% | -2.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $488.0M | +12.8% | +3.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 0.32 vs 0.27 | +20.2% | 0.04 vs 0.06 | -30.5% |
| Revenue Surprise | $276.3M vs $274.4M | +0.7% | $77.5M vs $78.0M | -0.7% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | MCLAUGHLIN KEVIN F | director | Common Stock | A | 7,000 | $13.05 |
| Aug 12, 2026 | MCLAUGHLIN KEVIN F | director | Common Stock | D | 7,000 | $44.53 |
| Aug 12, 2026 | MCLAUGHLIN KEVIN F | director | Stock Option (Right to Buy) | A | 7,000 | $13.05 |
| Aug 3, 2026 | Halpin Michael | officer: Chief Operating Officer | Common Stock | A | 10,000 | $16.66 |
| Aug 3, 2026 | Halpin Michael | officer: Chief Operating Officer | Stock Option (Right to Buy) | A | 10,000 | $16.66 |
Operator: Good day, and welcome to the Vericel Corporation First Quarter 2026 Earnings Call. [Operator Instructions] Today's conference is being recorded. At this time, I would like to turn the conference over to Eric Burns, Investor Relations. Please go ahead. Eric Burns: Thank you, operator, and good morning, everyone. Joining me on today's call are Vericel's President and Chief Executive Officer, Nick Colangelo; and our Chief Financial Officer, Joe Mara. Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially from expectations are discussed more fully in the company's most recent filings with the SEC. Also, the discussions today will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Vericel's current report on Form 8-K filed today with the SEC. A short presentation with highlights from today's call is also available in the Investor Relations section of our website. I will now turn the call over to Nick. Dominick C. Colangelo: Thank you, Eric, and good morning, everyone. The company had a great first quarter as we delivered outstanding financial and commercial results across the business and achieved a number of key business objectives that position the company to continue to generate strong revenue, profit and cash flow growth in 2026. The company generated record first quarter total revenue of more than $68 million, which increased 30% over last year and significantly exceeded our guidance for the quarter, driven by substantial growth for both MACI and the Burn Care business. This strong revenue performance drove significant margin expansion and profit growth as gross margin increased over 300 basis points, adjusted EBITDA margin increased nearly 800 basis points and adjusted EBITDA tripled to nearly $10 million. We also generated more than $15 million of free cash flow, ending the first quarter with over $210 million in cash and investments as we continue to strengthen the company's top-tier financial profile. Based on our first quarter outperformance, the significant momentum across the business that has continued with a strong start to the second quarter and the NexoBrid BARDA procurement revenue expected in the second half of the year, we're raising our total revenue guidance range by $10 million for the full year. MACI had another great quarter as double-digit volume growth drove record first quarter revenue of more than $56 million, representing 22% growth versus the prior year. Notably, MACI's trailing 4-quarter revenue growth rate increased to 23% compared to 19% in the prior four quarters, as we continue to execute on our strategic initiatives to deliver sustained high revenue growth for MACI. To that end, we're capitalizing on our larger MACI sales force, which …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Dominick C. Colangelo | Chief Executive Officer, President & Director | USD 1,735,451 | Male | 1964 | Active |
Michael Halpin | Chief Operating Officer | USD 913,869 | Male | 1962 | Active |
Joseph Anthony Mara Jr. | Chief Financial Officer & Treasurer | USD 854,869 | Male | 1976 | Active |
Jonathan Hopper FRCSEd. | Chief Medical Officer | USD 755,885 | — | 1962 | Active |
Sean C. Flynn | Chief Legal Officer | USD 740,669 | Male | 1974 | Active |
Eric Burns | Vice President of Finance & Investor Relations | — | Male | — | Active |
Jonathan Siegal | Principal Accounting Officer, Vice President & Corporate Controller | — | Male | — | Active |
Mike Gilligan | Senior Vice President of Sales | — | Male | — | Active |
Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy | — | Male | — | Active |
Roland DeAngelis | Chief Marketing Officer | — | Male | — | Active |
Bank of America Corp DE boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 19.7% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 1,098,771 shares of the biotechnology company's stock after buying an additional 180,761 shares during the period. Bank of America Corp DE owned
Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.
Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript
Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago.
Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Directors Authorizes $200 Million Share Repurchase Program Conference Call Today at 8:30am Eastern Time BURLINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2026.
